» Articles » PMID: 28077643

Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain

Abstract

Simian immunodeficiency viruses (SIVs) use their Nef proteins to counteract the restriction factor tetherin. However, a deletion in human tetherin prevents antagonism by the Nef proteins of SIVcpz and SIVgor, which represent the ape precursors of human immunodeficiency virus type 1 (HIV-1). To promote virus release from infected cells, pandemic HIV-1 group M strains evolved Vpu as a tetherin antagonist, while the Nef protein of less widespread HIV-1 group O strains acquired the ability to target a region adjacent to this deletion. In this study, we identified an unusual HIV-1 group O strain (RBF206) that evolved Vpu as an effective antagonist of human tetherin. While both RBF206 Vpu and Nef exert anti-tetherin activity in transient-transfection assays, mainly Vpu promotes RBF206 release in infected CD4 T cells. Although mutations distinct from the adaptive changes observed in group M Vpus (M-Vpus) were critical for the acquisition of its anti-tetherin activity, RBF206 O-Vpu potently suppresses NF-κB activation and reduces CD4 cell surface expression. Interestingly, RBF206 Vpu counteracts tetherin in a largely species-independent manner, degrading both the long and short isoforms of human tetherin. Downmodulation of CD4, but not counteraction of tetherin, by RBF206 Vpu was dependent on the cellular ubiquitin ligase machinery. Our data present the first example of an HIV-1 group O Vpu that efficiently antagonizes human tetherin and suggest that counteraction by O-Nefs may be suboptimal. Previous studies showed that HIV-1 groups M and O evolved two alternative strategies to counteract the human ortholog of the restriction factor tetherin. While HIV-1 group M switched from Nef to Vpu due to a deletion in the cytoplasmic domain of human tetherin, HIV-1 group O, which lacks Vpu-mediated anti-tetherin activity, acquired a Nef protein that is able to target a region adjacent to the deletion. Here we report an unusual exception, identifying a strain of HIV-1 group O (RBF206) whose Vpu protein evolved an effective antagonism of human tetherin. Interestingly, the adaptive changes in RBF206 Vpu are distinct from those found in M-Vpus and mediate efficient counteraction of both the long and short isoforms of this restriction factor. Our results further illustrate the enormous flexibility of HIV-1 in counteracting human defense mechanisms.

Citing Articles

Involvement of Human Cellular Proteins and Structures in Realization of the HIV Life Cycle: A Comprehensive Review, 2024.

Schemelev A, Davydenko V, Ostankova Y, Reingardt D, Serikova E, Zueva E Viruses. 2024; 16(11).

PMID: 39599797 PMC: 11599013. DOI: 10.3390/v16111682.


In vitro replicative potential of an HIV-1/MO intergroup recombinant virus compared to HIV-1/M and HIV-1/O parental viruses.

Moisan A, Tombette F, Vautrin M, Alessandri-Gradt E, Mourez T, Plantier J Sci Rep. 2024; 14(1):1730.

PMID: 38242913 PMC: 10799055. DOI: 10.1038/s41598-024-51873-3.


HIV-Host Cell Interactions.

Masenga S, Mweene B, Luwaya E, Muchaili L, Chona M, Kirabo A Cells. 2023; 12(10.

PMID: 37408185 PMC: 10216808. DOI: 10.3390/cells12101351.


A snapshot on HIV-1 evolution through the identification of phylogenetic-specific properties of HIV-1 integrases M/O.

Toccafondi E, Kanja M, Winter F, Lener D, Negroni M PLoS Pathog. 2023; 19(3):e1011207.

PMID: 36996029 PMC: 10062586. DOI: 10.1371/journal.ppat.1011207.


Evasion of cGAS and TRIM5 defines pandemic HIV.

Zuliani-Alvarez L, Govasli M, Rasaiyaah J, Monit C, Perry S, Sumner R Nat Microbiol. 2022; 7(11):1762-1776.

PMID: 36289397 PMC: 9613477. DOI: 10.1038/s41564-022-01247-0.


References
1.
Gaddis N, Sheehy A, Ahmad K, Swanson C, Bishop K, Beer B . Further investigation of simian immunodeficiency virus Vif function in human cells. J Virol. 2004; 78(21):12041-6. PMC: 523299. DOI: 10.1128/JVI.78.21.12041-12046.2004. View

2.
Bego M, Cong L, Mack K, Kirchhoff F, Cohen E . Differential Control of BST2 Restriction and Plasmacytoid Dendritic Cell Antiviral Response by Antagonists Encoded by HIV-1 Group M and O Strains. J Virol. 2016; 90(22):10236-10246. PMC: 5105659. DOI: 10.1128/JVI.01131-16. View

3.
Miyagi E, Andrew A, Kao S, Strebel K . Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci U S A. 2009; 106(8):2868-73. PMC: 2650357. DOI: 10.1073/pnas.0813223106. View

4.
Morchoisne S, Dugast M, Le Gall S, Raposo G, Schwartz O, Benaroch P . HIV-1 Nef impairs MHC class II antigen presentation and surface expression. Proc Natl Acad Sci U S A. 2001; 98(21):12144-9. PMC: 59782. DOI: 10.1073/pnas.221256498. View

5.
Gotz N, Sauter D, Usmani S, Fritz J, Goffinet C, Heigele A . Reacquisition of Nef-mediated tetherin antagonism in a single in vivo passage of HIV-1 through its original chimpanzee host. Cell Host Microbe. 2012; 12(3):373-80. PMC: 3444822. DOI: 10.1016/j.chom.2012.07.008. View